Stereotaxis Inc. (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has reported its financial results for the second quarter ended June 30, 2025. The company recorded an operating loss of $4.0 million and a net loss of $3.8 million for the quarter, showing improvement from the previous year's losses of $6.0 million and $5.8 million, respectively. Adjusted operating loss and adjusted net loss, excluding non-cash charges, were $1.4 million and $1.3 million, respectively, compared to $3.5 million and $3.3 million in the previous year. The company's cash and cash equivalents stood at $7.0 million with no debt as of June 30, 2025. In July, Stereotaxis raised $12.5 million in a registered direct financing, with $8.5 million received by the end of that month, leading to a proforma cash balance of $18.8 million. Stereotaxis has reiterated its expectation of double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue expected to scale to $7 million by the fourth quarter. The company anticipates substantial growth in 2026, following anticipated regulatory milestones and initial commercial launches in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.